CFA
BHVN

Compass Financial Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Compass Financial Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,653
Closed -$387K – 128
2022
Q2 		$387K Sell
2,653
-600
-18% -$76.6K 0.53% 68
2022
Q1 		$386K Sell
3,253
-652
-17% -$81.3K 0.43% 84
2021
Q4 		$538K Buy
+3,905
New +$497K 0.59% 65

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Compass Financial Advisors's BHVN Position: Q3 2022 in Review

Compass Financial Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 2,653 shares — an estimated $387K sold.

Compass Financial Advisors first reported a position in BHVN in Q4 2021 and held it in 3 quarters. The position peaked at $538K in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Compass Financial Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Compass Financial Advisors sold 2,653 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $387K.
  • Compass Financial Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 3 quarters.
  • Compass Financial Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $538K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Compass Financial Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.